-
-
J Korean Neurol Assoc. 2009;27(2):163-169.
- Efficacy and Safety of Autologous Bone Marrow-derived Mesenchymal Stem Cell Treatment in Patients With Amyotrophic Lateral Sclerosis
-
Hyun Young Kim
-
Department of Neurology, College of Medicine, Hanyang University Hospital, Seoul, Korea; Bioengineering Institute,
CoreStem Inc., Seoul, Koreaa; Division of Molecular and Life Sciences, Hanyang University, Ansan, Koreab; Department
of Anatomy and Cell Biology, College of Medicine, Hanyang University, Seoul, Koreac
- 근위축성측삭경화증 환자에서 자가 골수유래
중간엽줄기세포치료의 유효성 및 안전성
-
김현영, 백진영a 박희경 최미란b 윤현수c 김경숙a 김승현
-
한양대학교 의과대학 신경과학교실, 코아스템a, 한양대학교 과학기술대학 분자생물과학부b,
한양대학교 의과대학 해부세포생물학교실
- Abstract
- Background
This study was performed to investigate the efficacy and safety of intrathecal autologous bone marrowderived
mesenchymal stem cells (MSCs) treatment for patients with ALS.
Methods
After a lead-in period for 3 months, 22 patients were treated with MSCs twice at an interval of 1 month. After
initial MSCs injection, all patients were followed up for 3 months and their disease course, clinical characteristics were
assessed. Disease status of patients were analyzed with ALS functional rating scale-revised (ALSFRS-R) for primary
outcome measure, and additional clinical findings after treatment were all collected for secondary outcome measure and
safety. Age and disease-duration matched patients with ALS were selected as a control group.
Results
During the follow-up period, MSCs treatment yielded a significant lesser change of ALSFRS-R score, compared
to control group (1.54 vs 3.56, p<0.01). Moreover, the slop of decline of ALSFRS-R was significantly lower during the
follow-up period, compared to the lead-in period in MSCs treatment group (2.68 vs 1.54, p=0.04), whereas the slopes
during the two periods were not different in the control group (3.15 vs 3.56, p=0.37). MSCs treatment was well tolerated
except for occurrences of transient headache, low back pain, and myalgia.
Conclusions
Our results show that intrathecal MSCs injection can slow disease progression and might be used as a
disease modifying modality as an alternative treatment choice in patients with ALS. Key Words: Autologous bone marrow-derived mesenchymal stem cell, Amyotrophic lateral sclerosis, Efficacy, Safety
Keywords :
- 초록
-
